EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Actionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non–Small Cell Lung Cancer

Dwight Owen, Rotem Ben-Shachar, Josephine Feliciano, Lisa Gai, Kyle A Beauchamp, Zachary Rivers, Adam J Hockenberry, Genelle Harrison, John Guittar, Catarina Catela, Jerod Parsons, Ezra Cohen und 5 weitere

JAMA Network Open · 04.11.2024 · 7 (11) · e2442970

DOI: 10.1001/jamanetworkopen.2024.42970 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Network Open, online erschienen am 04.11.2024. Verfasst von Dwight Owen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Ohio State University School of Medicine, Columbus. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The National Comprehensive Cancer Network (NCCN) guidelines for non–small cell lung cancer suggest that RNA next-generation sequencing (NGS) may improve the detection of fusions and splicing variants compared with DNA-NGS alone. However, there is limited adoption of RNA-NGS in routine oncology clinical care today.

Objective

To analyze clinical evidence from a diverse cohort of patients with advanced lung adenocarcinoma and compare the detection of NCCN-recommended actionable structural variants (aSVs; fusions and splicing variants) via concurrent DNA and RNA-NGS vs DNA-NGS alone. Design, Setting, and Participants This multisite, retrospective cohort study examined patients sequenced between February 2021 and October 2023 within the deidentified, Tempus multimodal database, consisting of linked molecular and clinical data. Participants included patients with advanced lung adenocarcinoma and sufficient tissue sample quantities for both RNA-NGS and DNA-NGS testing. Exposures Received results from RNA-NGS and DNA-NGS solid-tissue profiling assays. Main Outcomes and Measures Detection rates of NCCN guideline–based structural variants ( ALK , ROS1 , RET and NTRK1/2/3 fusions, as well as MET exon 14 skipping splicing alterations) found uniquely by RNA-NGS.

Results

In the evaluable cohort of 5570 patients, median (IQR) age was 67.8 (61.3-75.4) years, and 2989 patients (53.7%) were female. The prevalence of actionable structural variants detected by either RNA-NGS or DNA-NGS was 8.8% (n = 491), with 86.7% (n = 426) of these detected by DNA-NGS. Concurrent RNA-NGS and DNA-NGS identified 15.3% more patients harboring aSVs compared with DNA-NGS alone (491 vs 426 patients, respectively), including 14.3% more patients harboring actionable fusions (376 vs 329 patients) and 18.6% more patients harboring MET exon 14 skipping alterations (115 vs 97 patients). There was no significant association between the assay used for aSV detection and aSV-targeted therapeutic adoption or clinical outcome. Emerging structural variants (eSVs) were found to have a combined prevalence to be 0.7%, with only 47.5% of eSVs detected by DNA-NGS. Conclusions and Relevance In this cohort study, the detection of structural variants via concurrent RNA-NGS and DNA-NGS was higher across multiple NCCN-guideline recommended biomarkers compared with DNA-NGS alone, suggesting that RNA-NGS should be routinely implemented in the care of patients with advanced NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHigh-Throughput Nucleotide SequencingHumansFemaleMaleMiddle AgedRetrospective StudiesAgedSequence Analysis, RNASequence Analysis, DNA

Autor:innen und Institutionen

  • Ohio State University School of Medicine, Columbus.
  • Tempus AI Inc, Chicago, Illinois.
  • Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Northwestern University School of Medicine, Chicago, Illinois.
  • Washington University School of Medicine, St Louis, Missouri.

Zitieren

APA

Owen, D., Ben-Shachar, R., Feliciano, J., Gai, L., Beauchamp, K. A., Rivers, Z., Hockenberry, A. J., Harrison, G., Guittar, J., Catela, C., Parsons, J., Cohen, E., Sasser, K., Nimeiri, H., Guinney, J., Patel, J., & Morgensztern, D. (2024). Actionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non–Small Cell Lung Cancer. JAMA Network Open, 7(11), e2442970. https://doi.org/10.1001/jamanetworkopen.2024.42970

Vancouver

Owen D, Ben-Shachar R, Feliciano J, Gai L, Beauchamp KA, Rivers Z, et al. Actionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non–Small Cell Lung Cancer. JAMA Network Open. 2024;7(11):e2442970. doi:10.1001/jamanetworkopen.2024.42970

BibTeX
@article{Owen2024,
  author = {Owen, Dwight and Ben-Shachar, Rotem and Feliciano, Josephine and Gai, Lisa and Beauchamp, Kyle A and Rivers, Zachary and Hockenberry, Adam J and Harrison, Genelle and Guittar, John and Catela, Catarina and Parsons, Jerod and Cohen, Ezra and Sasser, Kate and Nimeiri, Halla and Guinney, Justin and Patel, Jyoti and Morgensztern, Daniel},
  title = {Actionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non–Small Cell Lung Cancer},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {11},
  pages = {e2442970},
  doi = {10.1001/jamanetworkopen.2024.42970}
}
Kostenlos starten →